How research peptides are made, and where the impurities come from
For qualified researchers. Clarion Peptides products are sold for laboratory research use only. They are not for people or animals. Updated November 10, 2026.
The short answer. Most synthetic peptides are built one amino acid at a time, on tiny beads. Each step almost always works, but not every time. The misses add up over a long chain. They leave short chains, chains missing one piece, and other close cousins in the mix. Purification removes most of them. The purity number on a lab report tells you how much is left.
Building on a bead
In 1963, Bruce Merrifield showed that a peptide could be built while its first amino acid is anchored to a solid bead.1 Because the chain stays stuck to the bead, every leftover chemical can be washed away after each step. Today the most common version is called Fmoc solid-phase synthesis. A 2016 review calls it the method of choice for making peptides.2
One step, repeated
Each new amino acid arrives with a chemical cap, called Fmoc, on its amino end. That cap stops it from joining itself. Its side chain carries a different cap, if it needs one. Then the cycle runs:
- Uncap. A mild base, usually piperidine, removes the Fmoc cap from the end of the growing chain.2
- Join. The next capped amino acid is activated and joined to the chain.
- Wash. Everything that did not stick to the bead is rinsed off.2
The cycle repeats once for each amino acid. At the end, a strong acid, trifluoroacetic acid (TFA), cuts the chain off the bead and strips the side-chain caps.2 The peptide usually comes away as a salt with TFA. That salt partner has weight. See HPLC purity vs peptide content.4
Why small misses add up
If one join fails, that chain ends up missing an amino acid. The misses multiply over the length of the chain. The table shows the share of chains with every join done. The column headers are made-up success rates for each join. Selank has 7 amino acids, so 6 joins; BPC-157 has 15; Thymosin Alpha-1 has 28.
| Peptide | 99.5% | 99% | 98% |
| Selank, 6 joins | 97% | 94% | 89% |
| BPC-157, 14 joins | 93% | 87% | 75% |
| Thymosin Alpha-1, 27 joins | 87% | 76% | 58% |
Made-up success rates, to show the math. Not data from any real batch.
A short chain like Selank is barely touched. A 28-amino-acid chain like Thymosin Alpha-1 loses much more to the same small error rate. The failed chains do not vanish. They stay in the crude product as close cousins of the target.
What else ends up in the mix
- Deletion chains. The full chain minus one amino acid. On a mass spectrum it shows up lighter by the weight of the missing piece, for example 57.02 less for a missing glycine.
- Short chains. Chains that stopped growing partway.
- Aspartimide products. The review calls aspartimide formation the most serious side reaction in Fmoc chemistry. It is a bigger problem when a sequence has several aspartic acids.2 BPC-157 has 2. Thymosin Alpha-1 has 3.5
- Flipped building blocks. An amino acid can flip to its mirror-image form while it is being joined.3 The Fmoc cap helps keep this low.2 See D and L amino acids.
- Clumping on the bead. For long chains, the review names chains sticking to each other on the bead as the major obstacle.2
How the cousins are removed and measured
The crude peptide is cleaned up by HPLC: the mix runs through a column, and the main peptide is collected while most cousins are left behind. A later test HPLC run gives the purity number, the share of the signal in the main peak. Many cousins are so close to the target that a small amount stays. That remainder is what the last fraction of a percent on a purity number describes.
A whole-molecule mass shows the main peak is the right molecule. Fragment data can show the order of its pieces. See what a mass match can’t tell you and Is 99.0% a pass?
What we can and can’t tell you
We do not make peptides. A contract synthesis lab makes them for us. Our lab reports test the finished powder, not the synthesis process. They give a purity number and, on our Freedom Diagnostics reports, a chromatogram and an identity check by mass. They do not name the impurities in the remaining fraction of a percent.
If your work is sensitive to a particular impurity, such as a deletion chain or an aspartimide product, ask for the impurity data before you buy.
Sources
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025.
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. doi:10.1002/psc.2836. PMID 26785684.
- Duengo S, et al. Epimerisation in peptide synthesis. Molecules. 2023;28(24):8017. PMID 38138507.
- Sikora K, et al. The role of counter-ions in peptides: an overview. Pharmaceuticals (Basel). 2020;13(12):442. PMID 33287352.
- Sequences: PubChem BPC-157, Thymosin Alpha-1, Epitalon.
All Clarion Peptides products are for laboratory research use only. Not for human or veterinary use. Nothing on this page is a claim about the effects of any compound.
